Buoyed by the success of the Bayer AG-partnered prostate cancer drug Nubeqa, Orion Pharma Ltd. has decided to refocus its R&D on oncology and pain and halt investment in neurodegenerative and rare diseases.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?